Non-cash equity consideration received from early-stage customers

SaaS vendors running startup or accelerator programs sometimes accept equity or warrants in the customer instead of cash for subscription fees, and this non-cash consideration must be measured at fair value, which is often highly uncertain for illiquid, early-stage private companies; getting this wrong either overstates revenue on a speculative valuation or, just as damaging, results in no revenue being recognized at all for a subscription that was genuinely delivered.

Can the fair value of the equity or warrant instrument received be reliably estimated at contract inception using observable valuation evidence, such as a recent priced funding round? If fair value cannot be reasonably estimated, is the residual approach (reference to the standalone selling price of the service provided) applied instead? How is subsequent fair value movement in the equity instrument received accounted for, and is it kept separate from the revenue transaction itself?

1. Confirm the equity or warrant instrument received is genuinely non-cash consideration for the subscription (not a separate investment transaction unrelated to the revenue contract), by checking that its receipt is contractually tied to the provision of the SaaS service.
2. Attempt to measure the non-cash consideration at its fair value at contract inception using an appropriate valuation approach for the specific instrument (e.g., a recent priced funding round for the equity, or an option-pricing model for warrants).
3. If fair value cannot be reasonably estimated because the instrument is too illiquid, early-stage, or lacks sufficient observable inputs, do not default to recognizing no revenue; instead measure the consideration (and therefore revenue) indirectly by reference to the standalone selling price of the subscription service promised, i.e., what a comparable cash-paying customer would be charged.
4. Recognize revenue for the subscription performance obligation over time as access is delivered, using the fair-value or SSP-based transaction price determined in steps 2-3, regardless of when or whether the equity instrument itself is formally transferred.
5. Separately from the revenue transaction, classify and account for the equity or warrant instrument received as a financial asset under IFRS 9 (or evaluate for associate/joint venture accounting if the stake conveys significant influence), initially recognized at the same fair value used for revenue measurement where determinable, or at the SSP-implied amount where fair value could not be directly estimated.
6. Track the investment separately post-recognition, applying fair value through profit or loss (or other applicable classification) at each subsequent reporting date, distinct from the revenue already recognized.

Measure the transaction price at the fair value of the equity or warrant instrument at contract inception where reasonably estimable, using valuation evidence such as a contemporaneous priced funding round, a recognized option-pricing model, or comparable company multiples applied cautiously given illiquidity. Where fair value cannot be reasonably estimated, measure the transaction price indirectly at the standalone selling price the entity would charge a comparable cash-paying customer for the same subscription scope. Subsequently measure the equity or warrant instrument itself under IFRS 9, typically at fair value through profit or loss unless another classification applies, independent of how the initial revenue transaction price was determined.

Disclose: the nature and terms of non-cash equity or warrant consideration arrangements with early-stage customers; the valuation approach used (direct fair value versus the standalone selling price fallback) and the reason for the chosen approach; the amount of revenue recognized under such arrangements during the period; the classification and subsequent measurement basis of the equity or warrant instruments received; the extent of estimation uncertainty involved, given the illiquid nature of the instruments.

• Recognizing no revenue at all because cash was not received, treating the arrangement as if no performance obligation existed simply because payment took a non-cash form
• using a speculative or unsupported valuation of illiquid early-stage equity instead of falling back on the standalone selling price when fair value truly cannot be reasonably estimated
• conflating the revenue transaction price with the subsequent measurement of the equity instrument, applying the same figure to both without distinguishing initial revenue recognition from ongoing investment accounting
• failing to reassess whether the equity stake conveys significant influence, which would require a different accounting model for the investment than a simple financial asset.